RENO, NV, Sept. 24 /PRNewswire-FirstCall/ -- ChromoCure, Inc. (PINKSHEETS: KKUR) announced today it has added regional sales and executive offices in Aventura Florida with Dr. Jay Ellenby. Dr. Ellenby will provide sales support and business development for the Southeastern United States. Dr. Ellenby is a member of the Company's Board of Advisors and will be the Business and Sales Director for the entire Southeastern United States. Today's announcement and the recent appointment of the Company's Lead Pathologist Dr. Mikhail Kantius to the Board of Advisors is a continuation of the Company's strategic plans to establish regional sales and executive offices to promote and distribute the Company's technology and solutions. The Company now has business development team member for both the Northeastern and Southeastern United States. Updates will be released on the following strategic goals: - Initial sales and installations of the Company's systems and technology - Acquisition of profitable diagnostic labs to expand the company's operations - Release of technology and industry White Papers, industry commentary, and sales revenue models. About ChromoCure ChromoCure develops and provides proprietary cancer detection systems. The Company owns its technology and provides its systems on a revenue sharing basis. The Company's systems measure the unique genomic characteristic found in 100% of all cancers and never found in normal cells. The Company believes its technology has an effective accuracy of 100% for all cancers at all stages. The Company believes its technology superior and will become the gold standard for cancer detection worldwide. The Company's technology and understanding of cancer also suggest non-toxic and non-invasive approaches to cancer therapy and cure research. The Company will release progress reports on these initiatives from time to time. Safe-Harbor Statement This release contains statements or projections regarding future performance that are forward-looking statements as defined in the Private Securities Litigation Reform Act of 1995. Actual results may differ materially from those projected as a result of certain risks and uncertainties. The company's filings contain various RISK FACTORS (and are incorporated herein by reference) and should be read before any investment decision. Investor Relations: Contact: ChromoCure, Inc. Tel 1.775.636.6548 DATASOURCE: ChromoCure, Inc. CONTACT: ChromoCure, Inc., , Tel (775) 636-6548

Copyright